Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP, Research and Development | June 01, 2019 | June 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 01, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,399.222 |
Reported balance
After 2019-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-06-01 · Tax withholding · Disposed 460 · Balance 7,399.222 F1: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019. |
| Common StockSEC Table I · non-derivative | Direct | 8,525.222 |
Reported balance
After 2019-06-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-06-01 · Exercise / conversion · Acquired 1,126 · Balance 8,525.222 |
| Common StockSEC Table I · non-derivative | Direct | 8,025.222 |
Reported balance
After 2019-06-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2019-06-01 · Tax withholding · Disposed 500 · Balance 8,025.222 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-06-01 | Direct | 1,376 |
Reported balance
After 2019-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-06-01 · Exercise / conversion · Disposed 1,126 · Balance 1,376 F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-06-01 | Direct | 0 |
Reported balance
After 2019-06-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-06-01 · Other · Disposed 1,376 · Balance 0 F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019.
F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,376 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · derivative · entry 5 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,376 shares Expires 2019-06-01 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,126 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · derivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,126 shares Expires 2019-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 500 | $219.29 | $109,645.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · nonDerivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,025.222 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,525.222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 460 | $219.29 | $100,873.40 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,399.222 F1 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:54 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,033 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007251 · form4.xml · derivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,724 Underlying: Common Stock · 1,033 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,685 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007251 · form4.xml · derivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,757 Underlying: Common Stock · 1,685 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 749 | $332.87 | $249,319.63 |
DisclosureSEC source: 0001127602-19-007251 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,777.171 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007251 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,526.171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 13,460 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · derivative · entry 8 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,460 Underlying: Common Stock · 13,460 shares Expires 2022-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,697 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · derivative · entry 7 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,894 Underlying: Common Stock · 1,697 shares Expires 2021-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,249 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · derivative · entry 6 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,591 Underlying: Common Stock · 2,249 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,578 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · derivative · entry 5 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,157 Underlying: Common Stock · 1,578 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 798 | $319.43 | $254,905.14 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,841.171 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,639.171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 469 | $319.43 | $149,812.67 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,390.171 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,859.171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 20:16 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 1,000 | $350.00 | $350,000.00 |
DisclosureSEC source: 0001127602-18-028453 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,281.171 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:31 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,110 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020025 · form4.xml · derivative · entry 5 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,502 Underlying: Common Stock · 1,110 shares Expires 2019-06-01 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,384 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020025 · form4.xml · derivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,612 Underlying: Common Stock · 1,384 shares Expires 2019-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 616 | $297.09 | $183,007.44 |
DisclosureSEC source: 0001127602-18-020025 · form4.xml · nonDerivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,281.171 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020025 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897.171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 460 | $297.09 | $136,661.40 |
DisclosureSEC source: 0001127602-18-020025 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,513.171 F1 · balance_after: Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,006 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007195 · form4.xml · derivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,442 Underlying: Common Stock · 1,006 shares Expires 2020-02-15 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007195 · form4.xml · derivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,448 Underlying: Common Stock · 1,712 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 509 | $299.38 | $152,384.42 |
DisclosureSEC source: 0001127602-18-007195 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,898.359 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007195 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,407.359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39.569 shares and 39.790 shares acquired under the Biogen Inc. employee stock purchase plan on 9/29/2017 and 12/29/2017, respectively. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:46 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 11,840 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006193 · form4.xml · derivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Underlying: Common Stock · 11,840 shares Expires 2021-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:46 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 4,735 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006193 · form4.xml · derivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,735 Underlying: Common Stock · 4,735 shares Expires 2020-02-12 F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:38 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,235 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-020555 · form4.xml · derivative · entry 5 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,996 Underlying: Common Stock · 1,235 shares Expires 2019-06-01 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F4 · derivative.underlying_shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-020555 · form4.xml · derivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 Underlying: Common Stock · 1,259 shares Expires 2019-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This award was previously reported as covering 7,320 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F2 · derivative.underlying_shares: This award was previously reported as covering 7,320 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F2 · balance_after: This award was previously reported as covering 7,320 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 411 | $252.38 | $103,728.18 |
DisclosureSEC source: 0001127602-17-020555 · form4.xml · nonDerivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-020555 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 336 | $252.38 | $84,799.68 |
DisclosureSEC source: 0001127602-17-020555 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,768 F1 · balance_after: On June 1, 2016 an RSU was awarded for 3,034 shares. This award was adjusted to 3,104 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:22 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,160 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007110 · form4.xml · derivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 Underlying: Common Stock · 8,160 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.